[go: up one dir, main page]

MX2017011600A - Terapeuticos de anticuerpo que enlazan antigeno de membrana especifico de prostata. - Google Patents

Terapeuticos de anticuerpo que enlazan antigeno de membrana especifico de prostata.

Info

Publication number
MX2017011600A
MX2017011600A MX2017011600A MX2017011600A MX2017011600A MX 2017011600 A MX2017011600 A MX 2017011600A MX 2017011600 A MX2017011600 A MX 2017011600A MX 2017011600 A MX2017011600 A MX 2017011600A MX 2017011600 A MX2017011600 A MX 2017011600A
Authority
MX
Mexico
Prior art keywords
antibodies
psma
fragments
disclosed
derivatives
Prior art date
Application number
MX2017011600A
Other languages
English (en)
Inventor
Zhou Heyue
Gros Edwige
Yalamanchili Silpa
Original Assignee
Sorrento Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sorrento Therapeutics Inc filed Critical Sorrento Therapeutics Inc
Publication of MX2017011600A publication Critical patent/MX2017011600A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68031—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being an auristatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A61K47/6829—Bacterial toxins, e.g. diphteria toxins or Pseudomonas exotoxin A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6869—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from a cell of the reproductive system: ovaria, uterus, testes, prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Reproductive Health (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Se describen composiciones y métodos relacionados con o derivados de anticuerpos anti-PSMA. Más específicamente, se describe anticuerpos completamente humanos que enlazan PSMA, fragmentos de enlace a anticuerpo PSMA y derivados de tales anticuerpos, y polipéptidos de enlace a PSMA que comprenden tales fragmentos. Todavía además, se describe ácidos nucleicos que codifican tales anticuerpos, fragmentos de anticuerpos y derivados y polipéptidos, células que comprenden tales polinucleótidos, métodos para preparar tales anticuerpos, fragmentos de anticuerpos y derivados y polipéptidos, y métodos para usar tales anticuerpos, fragmentos y derivados de anticuerpo y polipéptidos, incluyendo métodos para tratar una enfermedad. Además, se describe terapias dirigidas para el tratamiento de cáncer de próstata que tiene los anticuerpos anti-PSMA descritos y fragmentos de los mismos que dirigen el agente o célula terapéuticos.
MX2017011600A 2015-03-10 2016-03-10 Terapeuticos de anticuerpo que enlazan antigeno de membrana especifico de prostata. MX2017011600A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562131227P 2015-03-10 2015-03-10
PCT/US2016/021672 WO2016145139A1 (en) 2015-03-10 2016-03-10 Antibody therapeutics that bind psma

Publications (1)

Publication Number Publication Date
MX2017011600A true MX2017011600A (es) 2018-06-13

Family

ID=56879307

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017011600A MX2017011600A (es) 2015-03-10 2016-03-10 Terapeuticos de anticuerpo que enlazan antigeno de membrana especifico de prostata.

Country Status (12)

Country Link
US (2) US10100126B2 (es)
EP (1) EP3268039B1 (es)
JP (1) JP2018510865A (es)
KR (1) KR20180012740A (es)
CN (1) CN108025063A (es)
AR (1) AR104484A1 (es)
AU (1) AU2016229087A1 (es)
CA (1) CA2979219A1 (es)
IL (1) IL254310A0 (es)
MX (1) MX2017011600A (es)
TW (1) TW201639891A (es)
WO (1) WO2016145139A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2018209400B2 (en) 2017-01-20 2022-06-02 Juno Therapeutics Gmbh Cell surface conjugates and related cell compositions and methods
AU2018242152B2 (en) * 2017-03-30 2022-05-12 Ecs-Progastrin Sa Compositions and methods for detecting prostate cancer
WO2018187791A1 (en) 2017-04-07 2018-10-11 Juno Therapeutics, Inc Engineered cells expressing prostate-specific membrane antigen (psma) or a modified form thereof and related methods
AU2019324388A1 (en) 2018-08-20 2021-03-18 1Globe Biomedical Co., Ltd. Novel cancer immunotherapy antibody compositions
MX2022008381A (es) * 2020-01-06 2022-08-08 Cytomx Therapeutics Inc Compuestos relacionados con auristatina, compuestos conjugados de auristatina y metodos de uso de ellos.
CN111303288B (zh) * 2020-03-04 2020-12-25 和铂医药(苏州)有限公司 一种分离的结合抗原psma的蛋白及其用途
JP2023532807A (ja) 2020-07-08 2023-07-31 ラヴァ・セラピューティクス・エヌ・ヴイ Ｐｓｍａ及びガンマ－デルタｔ細胞受容体に結合する抗体
CN112480260B (zh) * 2020-12-09 2022-03-08 福州迈新生物技术开发有限公司 抗psma蛋白单克隆抗体、细胞系及其制备方法和应用
EP4676520A1 (en) 2023-03-03 2026-01-14 Arsenal Biosciences, Inc. Systems targeting psma and ca9

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6010902A (en) 1988-04-04 2000-01-04 Bristol-Meyers Squibb Company Antibody heteroconjugates and bispecific antibodies for use in regulation of lymphocyte activity
US5582996A (en) 1990-12-04 1996-12-10 The Wistar Institute Of Anatomy & Biology Bifunctional antibodies and method of preparing same
DE4118120A1 (de) 1991-06-03 1992-12-10 Behringwerke Ag Tetravalente bispezifische rezeptoren, ihre herstellung und verwendung
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
DE19728697C1 (de) * 1997-07-04 1999-03-25 Deutsches Krebsforsch Humaner Antikörper gegen ein Fusions(poly)peptid bzw. -protein, das einen Anteil von mindestens sechs Histidinen aufweist
GB9722131D0 (en) 1997-10-20 1997-12-17 Medical Res Council Method
GB9928787D0 (en) 1999-12-03 2000-02-02 Medical Res Council Direct screening method
US6938003B2 (en) 2000-06-30 2005-08-30 Mahesh Harpale Method and apparatus for a credibility reporting system to augment an online exchange
GB0025144D0 (en) 2000-10-13 2000-11-29 Medical Res Council Concatenated nucleic acid sequences
NZ534687A (en) * 2002-01-28 2007-10-26 Medarex Inc Human monoclonal antibodies to prostate specific membrane antigen (PSMA) seq id 54
US20040202995A1 (en) 2003-04-09 2004-10-14 Domantis Nucleic acids, proteins, and screening methods
CN101124249B (zh) * 2005-02-18 2011-06-29 米德列斯公司 抗前列腺特异性膜抗原（psma）的人单克隆抗体
CN101160324B (zh) * 2005-02-18 2013-04-24 米德列斯公司 缺乏岩藻糖残基的抗前列腺特异性膜抗原(psma)单克隆抗体
TW200813091A (en) * 2006-04-10 2008-03-16 Amgen Fremont Inc Targeted binding agents directed to uPAR and uses thereof
JOP20080381B1 (ar) 2007-08-23 2023-03-28 Amgen Inc بروتينات مرتبطة بمولدات مضادات تتفاعل مع بروبروتين كونفيرتاز سيتيليزين ككسين من النوع 9 (pcsk9)
US20110189093A1 (en) * 2008-04-14 2011-08-04 Proscan Rx Pharma Prostate specific membrane antigen antibodies and antigen binding fragments
EP2356270B1 (en) 2008-11-07 2016-08-24 Fabrus Llc Combinatorial antibody libraries and uses thereof
WO2010118522A1 (en) * 2009-04-14 2010-10-21 Proscan Rx Pharma Inc. Antibodies against prostate specific membrane antigen
US20120316071A1 (en) * 2009-11-04 2012-12-13 Vaughn Smider Methods for affinity maturation-based antibody optimization
CN103333249A (zh) * 2013-06-14 2013-10-02 广州康合生物科技有限公司 一种抗前列腺特异性膜抗原（psma）的单克隆抗体及其应用
RU2577228C2 (ru) * 2014-03-14 2016-03-10 Закрытое Акционерное Общество "Биокад" Анти-il-17-антитела, способ их получения и способ применения

Also Published As

Publication number Publication date
CN108025063A (zh) 2018-05-11
EP3268039A1 (en) 2018-01-17
EP3268039B1 (en) 2020-11-04
TW201639891A (zh) 2016-11-16
CA2979219A1 (en) 2016-09-15
WO2016145139A1 (en) 2016-09-15
IL254310A0 (en) 2017-11-30
AU2016229087A1 (en) 2017-09-28
US20160326264A1 (en) 2016-11-10
AR104484A1 (es) 2017-07-26
US20190010250A1 (en) 2019-01-10
JP2018510865A (ja) 2018-04-19
US10100126B2 (en) 2018-10-16
EP3268039A4 (en) 2018-08-01
KR20180012740A (ko) 2018-02-06

Similar Documents

Publication Publication Date Title
MX2017011600A (es) Terapeuticos de anticuerpo que enlazan antigeno de membrana especifico de prostata.
ZA202308021B (en) Anti-ctla4 antibodies and methods of making and using the same
SA518400424B1 (ar) جزيئات الجسم المضاد لعلاج السرطان
PH12019501959A1 (en) Therapeutic rna
MX2017011406A (es) Terapeuticos de anticuerpo que se unen a tim3.
MX2022008523A (es) Compuestos que interactuan con glicanos y metodos de uso.
MX2019006045A (es) Proteinas triespecificas dirigidas a psma y metodos de uso.
WO2016059602A3 (en) Combination therapy with anti-her3 antibodies to treat cancer
MY207784A (en) Anti-cd73 antibodies
PH12015500084A1 (en) Rspo3 binding agents and uses thereof
EA201790404A1 (ru) Макропиноцитозирующие человеческие анти-cd46 антитела и таргетная терапия рака
SG178930A1 (en) Therapeutic dll4 binding proteins
JOP20220079A1 (ar) بروتين ربط متعددة الخصوصية لمعالجة السرطان
NZ761094A (en) Diaryl macrocycles as modulators of protein kinases
WO2014004549A3 (en) Anti-mesothelin binding proteins
MX2018010331A (es) Agentes de ligacion al factor de crecimiento endotelial vascular/ligando 4 similar a delta (vegf/dll4) y usos de los mismos.
PH12017500331A1 (en) Antigen binding proteins that bind cxcr5
UA118354C2 (uk) Антитіло до рецептора колонієстимулювального фактора (кфс-1r)
PH12020551447A1 (en) Antibodies
MX2020005473A (es) Anticuerpos humanizados que se dirigen al factor tisular humano.
MX2022000242A (es) Anticuerpos contra ticagrelor y metodos de uso.
HK1250626A1 (zh) 借助塞里班土单抗的组合治疗
EA201491352A1 (ru) Способ лечения рака груди
PH12021551419A1 (en) New conjugated nucleic acid molecules and their uses
MX2017013666A (es) Terapia de combinacion de agente anti-fuctactico y agente de inmunoterapia y composiciones para el tratamiento de cancer.